Controlled drug trial of B.663 compared with DDS. Preliminary (48 week) report.
D000814:Aniline Compounds / Q000627:therapeutic use; D003622:Dapsone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007918:Leprosy / Q000150:complications / Q000188:drug therapy*; D009443:Neuritis / Q000139:chemically induced; D010619:Phenazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D000814:Aniline Compounds; D010619:Phenazines; D003622:Dapsone